Skip to main content

Concert Genetics, Trapelo Health to Integrate Technology for Oncology Decision Support

NEW YORK – Concert Genetics and Trapelo Health have agreed to integrate their technology to offer more comprehensive evidence-based molecular decision support for oncology, the companies said Thursday. They will deliver the service through Nashville, Tennessee-based Concert's network of health plans and genomics laboratories.

The firms said that their partnership seeks to improve connectivity and transparency to help clinicians make more informed decisions on molecular testing, cancer treatment, and recommending patients for clinical trials.

Burlington, Massachusetts-based startup Trapelo Health makes a clinical decision support system that links healthcare providers, testing laboratories, and payors, giving them access to molecular testing information and results interpretation in order to optimize utilization of molecular testing services and offer the most appropriate care to patients

"An increasing number of treatment decisions require both familial and somatic testing. Our collaboration gives stakeholders the resources and expertise to effectively manage genomic-informed decision making in the new age of cancer care," Trapelo CEO Clynt Taylor said in a statement.

"Achieving the promise of precision medicine requires bringing exactly the right data to bear at the moment of truth, when diagnosis is determined and treatment decisions are made," Concert Genetics CEO Rob Metcalf added. "Together, Concert and Trapelo can improve the quality and clarity of information available at that moment for the benefit of all stakeholders, especially the patient."